Similar articles

• Two new drugs for homozygous familial hyperchelesterolemia.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2013 Apr 1;55(1413):25-7. Med Lett Drugs Ther. 2013. PMID: 23545581 No abstract available.
• Mipomersen as a potential adjunctive therapy for hypercholesterolemia.

  Patel N, Hegele RA. Patel N, et al. Expert Opin Pharmacother. 2010 Oct;11(15):2569-72. doi: 10.1517/14656566.2010.512006. Expert Opin Pharmacother. 2010. PMID: 20707601 Review.
• Antisense technology to lower LDL cholesterol.

  Neely RD, Bassendine MF. Neely RD, et al. Lancet. 2010 Mar 20;375(9719):959-61. doi: 10.1016/S0140-6736(10)60364-9. Lancet. 2010. PMID: 20227757 No abstract available.
• [Controlling LDL cholesterol from 2 sides. "I have never seen such low LDL values"].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2003 May 15;145(20):59. MMW Fortschr Med. 2003. PMID: 12822234 German. No abstract available.
• Is mipomersen ready for clinical implementation? A transatlantic dilemma.

  Sjouke B, Balak DM, Beuers U, Ratziu V, Stroes ES. Sjouke B, et al. Curr Opin Lipidol. 2013 Aug;24(4):301-6. doi: 10.1097/MOL.0b013e328362dfd9. Curr Opin Lipidol. 2013. PMID: 23759796 Review.